RT Journal Article
SR Electronic
T1 Pharmacological treatment of COPD in the on-sint cohort
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P536
VO 44
IS Suppl 58
A1 Lucía Marín Barrera
A1 Cecilia López Ramírez
A1 José Luis López-Campos
A1 Carmen Calero Acuña
A1 Alberto Fernández-Villar
A1 Cristina Represas Represas
A1 Cristina Ramos Hernández
A1 Ricard Casamor
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P536.abstract
AB OBJECTIVE:Describe pharmacological treatment of COPD in patients included in the On-Sint cohort, both when diagnosed and at present.METHODS:Retrospective,multicenter observational study where patient data were collected from single medical visit and by reviewing medicals records.The cohort On-Sint was formed by adult COPD patients,smokers or ex-smokers(≥10 packs-years),who were regularly followed-up by 263 primary care physicians(PC) or 93 Pulmonologists(P).We describe and compare the pharmacological treatment(by therapeutic groups)that patients received upon diagnosis and at present stratified by the GOLD classification.Quantitative data expressed as mean(standard deviation)RESULTS:1214 patients met inclusion criteria(age of 66.4(9.7)years,78.7% male,857(70.6%)by PC).The average time interval from diagnosis to inclusion was 8(7.2)years.The different therapeutic group that each patient received upon diagnosis and at present according to 2010 GOLD stages,is indicated in the table.View this table:CONCLUSIONS:On-Sint cohort has detected an increase in the use of LABD and ICS,although the indication seems to be more consistent with the functional severity.Mucolytics are still excessively used.The use of all groups of treatment is lower for those with unknown GOLD stage.